NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NYSE American · Biotechnology · USD

Cybin Inc. (CYBN) Stock Analysis

Cybin Inc. (CYBN) is a Biotechnology stock listed on NYSE American and quoted in US Dollar.

CYBN

$6.81

−$0.09 (−1.30%)

Last trade February 20, 2026

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CYBN with… →

CYBN Key Statistics

As of Feb 20, 2026
Trading
Open
$6.86
Previous Close
$6.90
Day's Range
6.70–7.24
52-Week Range
4.81–10.72
Volume
385.37K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.79
Valuation
Market Cap
$413.12M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.77
Financials (FY)
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
1-Year Return
−27.01%
Dividend and dates
Avg Volume
874.38K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

CYBN Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−16.75%
2025−7.26%
2024 (partial year)−5.36%

As of February 20, 2026.

CYBN Valuation vs Biotechnology Median

Median of 656 stocks
MetricCYBNBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

The market values Cybin Inc. (CYBN) at $413.12M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 50 employees.

The 52-week range on file runs from $4.81 to $10.72. CYBN last closed at $6.81 on February 20, 2026. That is −$0.09 (−1.30%) against the previous close. The latest close sits 41.58% above that 52-week low.

Financial Health

The reported profit margin is 0%. Earnings per share on a trailing basis come to −3.77.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Over the trailing twelve months the price has returned −27.01%. Beta against the wider market is reported at 0.79. Annualized volatility over the trailing 1 year is 73%.

Growth & Income

No dividend is on file for CYBN.

The record holds one complete calendar year, 2025, which returned −7.26%. So far in 2026 the price is −16.75%.

Peer Comparison

Cybin Inc. (CYBN) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Cybin Inc. CYBN $413.12M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Cybin Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of February 20, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Cybin Inc.

Cybin Inc., a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company also develops SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat central nervous system, as well as has a research pipeline of investigational psychedelic-based compounds. It has a strategic partnership agreement with Segal Trials to support PARADIGM, a multinational pivotal phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder. The company is headquartered in Toronto, Canada.

Visit website →